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Summary
 
Objective
 
Andriol® Testocaps® is a new oral formulation of
testosterone undecanoate (TU) for treatment of hypogonadism. As
TU is taken up by the intestinal lymphatic system, both the presence
and the composition of food inﬂuence the absorption. The aim of
this study was to investigate the effect of food composition on the
pharmacokinetics of oral TU.
 
Design
 
An  open-label, single-centre, four-way crossover study.
With a washout period of 6–7 days, 80 mg TU was administered in
the morning 5 min after consuming each of four different meals in
a randomized order (A: 230 kcal, 0·6 g lipid; B: 220 kcal, 5 g lipid;
C: 474 kcal, 19 g lipid; D: 837 kcal, 44 g lipid).
 
Patients
 
Twenty-four postmenopausal volunteers.
 
Measurements
 
Serial blood samples were collected until 24 h after
dosing to determine testosterone and dihydrotestosterone (DHT) by
gas chromatography-mass spectroscopy (GC-MS).
 
Results
 
The bioavailability of testosterone after a low-calorie meal
containing 0·6 g lipid or 5 g lipid was relatively low, the area under
the concentration–time curve (AUC
 
0–tlast
 
) for testosterone being
30·7 and 43·5 nmol h/l, respectively. The bioavailability of testo-
sterone after a meal containing 19 g lipid was considerably higher
(AUC
 
0–tlast
 
 = 146 nmol h/l), whereas increasing the lipid content to
44 g lipid did not further increase the bioavailability of testosterone
(AUC
 
0–tlast
 
 = 154 nmol h/l).
 
Conclusion
 
Approximately 19  g of lipid per meal efﬁciently
increases absorption of testosterone from oral TU. Therefore, co-
administration with a normal rather than a fatty meal is sufﬁcient
to increase serum testosterone levels when using oral TU.
(Received 25 August 2006; returned for revision 11 October 2006; 
ﬁnally revised 16 November 2006; accepted 16 November 2006)
 
Introduction
 
Testosterone replacement therapy is intended to restore normal
serum testosterone levels in patients with hypogonadal disorders.
Although testosterone itself is absorbed well after oral administra-
tion, it is rapidly metabolized in the intestinal wall and during its
ﬁrst pass through the liver, thereby inactivating approximately 98%
of the amount absorbed. As a consequence, oral administration of
pure, crystalline testosterone does not increase serum testosterone
levels sufﬁciently. Such preparations are not therefore suitable for
oral administration in hypogonadal disorders, as they do not result
in sustained physiological serum testosterone levels.
 
1,2
 
 Various solutions
to  this problem have been developed, including injectable and
transdermal routes of administration as well as sophisticated systems
for oral administration that circumvent hepatic ﬁrst-pass metabo-
lism.
 
3
 
 Oral testosterone undecanoate (Andriol® Testocaps®) is the
only oral form of testosterone replacement therapy that restores
testosterone levels within the normal range and is available in more
than 80 countries. It consists of a solution of testosterone un-
decanoate (TU) in an oily vehicle, contained in a soft gelatin capsule.
 
4
 
In contrast to crystalline testosterone, TU dissolved in a lipophilic
solvent signiﬁcantly enhances absorption.
 
1
 
 De-esteriﬁcation of TU
to produce testosterone and 5
 
α
 
-reduction to produce dihydro-TU
(DHTU) take place rapidly in the intestinal wall as well as in the
peripheral circulation.
 
5–7
 
Many studies have shown that food can have a marked effect on
drug pharmacokinetics by increasing, decreasing and/or delaying
drug absorption.
 
8,9
 
 A study with oral TU in men has suggested that,
if taken with a meal, the TU molecules are included in chylomicrons.
As a result, a signiﬁcant part of the administered TU bypasses the
liver and gains access to the peripheral circulation through the intestinal
lymphatic system, thereby further increasing serum testosterone
levels.
 
10
 
 Recently, the effect of food on the bioavailability of oral TU
was investigated in more detail. In a single-dose, randomized cross-
over study, the effect of a standardized meal on the pharmacokinetics
of oral TU was compared with administration in a fasting state. It
was found that in the fasting state hardly any TU was absorbed and
oral administration of TU with food dramatically enhanced the bio-
availability of TU. It was concluded that for optimal absorption, oral
TU capsules must be taken with food.
 
11
 
 However, as this study con-
tained only one standardized type of meal, the optimal amount of
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food and which meal composition would be optimal for adequate
absorption of TU after oral administration could not be determined.
In the absence of clear guidelines, the advice has often been to take
oral TU capsules with a ‘fatty meal’ to ensure optimal absorption of
the active ingredient.
 
12
 
 From the patient’s perspective, this issue is
relevant because twice daily administration of the capsules with a
‘fatty meal’ is undesirable.
The aim of the current study was to investigate the effect of food
composition on the bioavailability of oral TU.
 
Methods
 
Pharmaceutical formulation
 
Andriol® Testocaps® are oval, orange, soft gelatin capsules containing
40 mg TU in castor oil with propylene glycol laurate [60 : 40 (w/w)],
glycerin and sunset yellow (E110). Within 5 min of each test meal,
the subjects received two capsules (total 80 mg) of oral TU.
 
Study centre
 
The clinical part of the study was performed at Pharm PlanNet
Contract Research GmbH, D-41061 Mönchengladbach, Germany. The
study protocol was approved by the Independent Ethics Committee
of the Physicians Chamber North-Rhine (Ärztekammer Nordrhein),
Düsseldorf, Germany. The trial was conducted in compliance with
the currently accepted revision of the Declaration of Helsinki, the
guidelines for Good Clinical Practice and Principles of Good
Laboratory Practice (GLP).
 
Subjects
 
A total of 24 healthy, postmenopausal women, aged 45–65 years and
with a body mass index (BMI) of 18–30 kg/m
 
2
 
, participated in this
study. To be considered for inclusion subjects had to provide written
informed consent before screening evaluations, and have a pretrial
screening total testosterone level < 2·5 nmol/l, smoking < 10 ciga-
rettes/day, be in good age-appropriate physical and mental health,
have a normal cervical smear performed within the past 12 months
and a normal mammogram performed within the past 24 months.
Subjects had to refrain from all use of grapefruit juice and caffeine
and other methylxanthines (e.g. coffee, tea, cola or chocolate) from 48 h
prior to each dosing until the last pharmacokinetic blood sampling,
24 h after each dosing. Subjects were excluded from the study if they
had a history of sensitivity to TU or chemically related substances
or used drugs known to alter oestrogen metabolism or affect cyto-
chrome P450 enzymes, except after an appropriate washout period.
Subjects were excluded if they had signs of severe acne or hirsutism,
or abnormal blood pressure or heart rates, were HIV or hepatitis
B/C positive. Subjects were also excluded if they had a history of
signiﬁcant allergic or other diseases, including malignancies, drug,
alcohol or solvent abuse, had donated blood or participated in an
investigative drug trial within 90 days before the start of this study
or during the study. Subjects were not allowed to use any prescription
or over-the-counter medication for 7 days before the ﬁrst dose until the
last pharmacokinetic sampling except for sporadic use of paracetamol.
 
Clinical study design and blood sampling
 
The study was an open-label, single-centre, four-period, crossover
design with a washout of 6–7 days between each treatment and the
follow-up. For logistic reasons the trial was performed in two cohorts
of 12 subjects. Volunteers were randomized to receive one of four
sequences of therapy. The sequences were characterized by the Latin
square sequence of the meals, which were either ABCD, BDAC,
CADB or DCBA. Volunteers fasted overnight (for at least 10 h) and
in the morning they received a single oral dose of 80 mg TU (two
capsules) with 150 ml water, exactly 5 min after the end of the A, B,
C or D meal, which they had consumed over a period of 10 min (A,
B), 15 min (C) or 20 min (D). Thereafter, subjects fasted for another
4 h (but after 1 h they were allowed to drink water 
 
ad libitum
 
), after
which a lunch was served; 10 h after breakfast, dinner was served and
in the evening a snack was served. Serial blood samples were taken
before dosing and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20 and
24 h after dosing with oral TU for determination of serum TU,
testosterone, DHTU and dihydrotestosterone (DHT). Immediately
after collection, blood was processed to serum, divided over two
tubes and stored in a freezer.
In this study the effects of four different meal compositions on
the pharmacokinetics of oral TU were investigated:
Meal A (‘fat-free’ meal) consisted of yoghurt (175 ml, 0·16% lipids),
250 ml milk (0·16% lipids) and 20 g sugar. The calculated total
amount of lipids was 0·7 g and the calculated caloric value was
215 kcal.
Meal B (‘low-fat’ meal) consisted of yoghurt (175 ml, 1·5% lipids),
250 ml milk (1·02% lipids) and 5 g sugar. The calculated total
amount of lipids was 5 g and the calculated caloric value was
215 kcal.
Meal C (‘normal’ meal) contained two bread rolls, one slice of cheese
(20 g, 40% lipids), one slice of ham (25 g), 20 g jam, 10 g marga-
rine and two cups caffeine-free coffee (300 ml). The calculated
total amount of lipids was 20 g and the calculated caloric value
was 430 kcal.
Meal D (‘fatty’ meal) consisted of two eggs fried with 5 g butter, two
strips of bacon, two slices of toast with 7·5 g butter, 4 oz (113 g)
hash brown potatoes and 8 oz (226 ml) of whole milk. The cal-
culated total amount of lipids was 50 g and the calculated caloric
value was 850 kcal.
A spare meal of types A, B, C and D was collected, frozen and send
to Analytico, Heerenveen, the Netherlands, for chemical analysis of
the contents of the meal regarding lipid content, carbohydrates,
proteins and caloric value.
The lunch consisted of cooked slices of turkey with a thick sauce
of mushrooms and green peppers, rice, one medium-sized apple,
lettuce and tomato with yoghurt dressing, yoghurt with fruit, totalling
900 kcal, 28 g lipids. The evening dinner consisted of two slices of
dark bread, 20 g margarine, one slice of cheese, one slice of cold meat,
rice salad with tomato and onions, totalling 746 kcal, 29 g lipids. In
the evening subjects were allowed an evening snack consisting of one
apple (81 kcal, 0·9 g lipids). Subjects were required to refrain from
consuming grapefruit juice, caffeine and other methylxanthines (e.g.
coffee, tea, cola or chocolate) from 48 h before dosing until the last
pharmacokinetic sampling of each dose. 
Food and bioavailability of oral TU
 
581
 
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, 
 
Clinical Endocrinology
 
, 
 
66
 
, 579–585
 
Analytical design
 
TU and DHTU concentrations were determined using a validated
liquid chromatographic (LC) assay with mass spectrometry (MS)
detection after solid-phase extraction. The extracts were quantiﬁed
by LC-MS using electrospray ionization in multireaction monitoring
(MRM) mode. The analysis of testosterone and DHT concentrations
in serum were assayed using a validated GC assay with MS detection after
solid-phase extraction, derivatization and liquid–liquid extraction
with 
 
n
 
-hexane.
Each analytical series of TU, DHTU, testosterone and DHT con-
sisted of patient samples, eight calibration samples (in duplicate),
three or four quality control (QC) samples (in triplicate), two blank
internal standard samples (in duplicate) and at least one blank serum
(TU and DHTU only) and one blank water sample. The lower limit
of quantiﬁcation was 0·438 nmol/l for TU, 0·436 nmol/l for DHTU,
0·347 nmol/l for testosterone and 0·344 nmol/l for DHT. The inter-
assay coefﬁcient of variation for the QC samples was in the range
4·8–11·0% for TU, 4·0–30·1% for DHTU, 2·3–5·8% for testosterone
and 4·5–11·9% for DHT. The accuracy of the QC samples was in the
range 93·9–100·3% for TU, 103·0–114·2% for DHTU, 99·2–102·9%
for testosterone and 91·7–102·2% for DHT. Bioanalysis was per-
formed at the Bioanalytics Section of the Department of Metabolism
and Kinetics, Organon Development GmbH, Waltrop, Germany
(now Department of Bioanalytics, Organon Development GmbH,
Waltrop) with validated methods, and in compliance with GLP
principles of the OECD.
 
Pharmacokinetic parameters
 
Pharmacokinetic parameters were calculated by subject and by treat-
ment from serum concentrations of TU, DHTU, testosterone and
DHT. Maximum serum concentrations (
 
C
 
max
 
) and time to 
 
C
 
max
 
(
 
t
 
max
 
) were taken from the measured serum concentration data. The
area under the concentration–time curve from zero to 
 
t
 
last
 
 (AUC
 
0–tlast
 
)
was calculated by means of the linear trapezoidal rule, where 
 
t
 
last
 
represented the last time point with a measurable concentration.
Descriptive statistics for the concentrations were only calculated if
at least two-thirds of the concentrations by time point were greater
than or equal to the lower limit of quantiﬁcation (LLOQ). If that
was the case, then the concentrations indicated as < LLOQ were
replaced by 0·5 
 
×
 
 LLOQ for the calculation of the descriptive statistics.
 
Statistical analysis
 
Bioequivalence testing was performed to compare the pharmacoki-
netics of oral TU under different food conditions, where meal C
treatment was taken as reference treatment and meals A, B and D as test
treatments. Meal B treatment was also compared to meal A treatment.
For 
 
C
 
max
 
 and AUC
 
0–tlast
 
 of TU, DHTU, testosterone and DHT, para-
metric point estimates of the true ratio ‘test/reference’ of geometric
least-squares means with their 90%  conﬁdence intervals (CIs)
derived from the analysis of variance (
 

 
) on log
 
e
 
-transformed
values (multiplicative model) were calculated. The effects included
in the 
 

 
 model used were, respectively: sequence, subject within
sequence, period, treatment and treatment 
 
×
 
 period (partial).
Effects were considered statistically signiﬁcant when 
 
P
 
 
 
≤
 
 0·05
(two-tailed). The acceptance range was 0·80–1·20. A meal effect was
considered absent if the 90% CI for 
 
C
 
max
 
 and AUC for testosterone and
DHT were fully contained within the acceptance range of 0·80–1·20.
Data pertaining to TU and DHTU were considered to be supportive.
For subjects where concentrations (of any analyte) throughout the
sampling period were below the LLOQ, a value of one-half of the
LLOQ was substituted for 
 
C
 
max
 
 and a value representing the AUC
resulting from a concentration of one-half of the LLOQ during 1 h
was substituted for AUC. For 
 
t
 
max
 
, classical hypothesis testing was
performed. Point estimates of and nonparametric 95% CIs for
median differences were calculated using the method of Walsh averages.
 
13
 
Results
 
Subjects
 
All 24 randomized subjects completed the study. Mean age, weight,
height and body mass index were 59 ± 4·2 years (range 50–65 years),
72·9 ± 9·9 kg  (range  54·1–89·2 kg),  163·5 ± 5·9 cm  (range  152–
174 cm) and 27·2 ± 3·1 kg/m
 
2
 
 (range 20·1–32·1 kg/m
 
2
 
), respectively.
All subjects were Caucasian women. Three subjects took concomitant
medication (naproxen, acetyl salicylic acid, ibuprofen and articaine).
Mean testosterone levels at inclusion were 1·8 ± 0·62 nmol/l (range
0·7–3·5 nmol/l).
During and after exposure to oral TU combined with meal A or
meal D, 12 out of 24 women experienced adverse events (AEs), in
ﬁve subjects these were classiﬁed as being drug related. After com-
bination of oral TU application and meal B, nine of 24 women (38%)
showed AEs and after treatment with oral TU and meal C, eight of
24 subjects (33%) reported an AE. No serious AEs or tolerability con-
cerns were noted and all events reported were mild or moderate. AEs
reported with a prevalence of > 10% were headache in 12 subjects
(50%), diarrhoea in three subjects (13%) and fatigue in three subjects
(13%). No ﬁndings of clinical relevance were indicated by electro-
cardiogram (ECG), physical examination, vital signs or laboratory
investigations as assessed on the day before ﬁrst dosing and 9 days
after the last dose.
 
Meals
 
Table 1 shows that the calculated amount of lipids does not differ
substantially from the measured amount of lipid, except in meal D
(50 g 
 
vs.
 
 44 g). No remarkable differences between the calculated and
Table 1. Results of the food analysis compared with the calculated contents
Analysis Meal A Meal B Meal C Meal D
Total lipids (g) 0·61 5·43 18·76 44·09
Protein (g) 13·3 17·3 18·2 42·6
Total carbohydrates (g) 42·4 24·6 57·1 65·2
Total energetic value (kcal/kJ) 230/991 220/897 474/1992 837/3509
Calculated total lipids (g) < 1 5 20 50
Calculated kcal 215 215 430 850 
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actual total energetic values were seen, except for meal C (430 kcal
 
vs.
 
 474 kcal), but this difference was still less than 10%.
 
Serum concentrations and pharmacokinetic parameters
 
The results of the serum concentrations of TU, DHTU, testosterone
and DHT after the different type of meals are shown in Fig. 1. In
general, meals A and B resulted in low exposure of all analytes. In
many instances and on many time points, the serum concentrations
were below or close to the LLOQ. Meals C and D resulted in much
higher exposure for all analytes. Table 2 summarizes the calculated
pharmacokinetic parameters and the results of the statistical analyses.
Values of 
 
C
 
max
 
 increased with increasing lipid content. However,
increasing the lipid content beyond 19  g (meal  D, 44  g) did not
increase the 
 
C
 
max
 
  further for any of the analytes. For the AUC,
increasing the lipid contents from < 1 to 5, 19 or 44 g resulted in an
ongoing increase in AUC for TU and DHTU. However, for testoster-
one and DHT no further increase was seen when lipid content > 19 g
was given. Lipid content did not have an effect on the 
 
t
 
max
 
 of TU and
DHTU; however, for testosterone and DHT a low lipid content
Fig. 1 Geometric mean concentration vs. time 
curves for TU, DHTU, testosterone (T) and DHT 
after single oral administration of 80 mg TU. All 
curves based on n = 24 subjects.
Parameter (units) Meal A Meal B Meal C Meal D
TU
Cmax (nmol/l) 20·2 (181) 47·8 (124)  372 (84·5) 382 (87·7)
tmax (h) 5·0 (2·0–11·0) 5·0 (2·0–7·0) 5·0 (2·0–7·0)  5·0 (2·0–12·0)
AUC0–tlast (nmol h/l) 41·7 (176)  103 (149)  848 (53·3) 1050 (46·7)
DHTU
Cmax (nmol/l) 10·4 (160) 22·2 (91·0)  150 (53·7) 174 (56·2)
tmax (h) 5·0 (3·0–12·0) 5·0 (4·0–8·0) 5·0 (2·0–8·0)  6·0 (2·0–12·0)
AUC0–tlast (nmol h/l) 27·1 (192) 66·8 (116)  479 (39·9) 677 (34·7)
Testosterone
Cmax (nmol/l) 4·65 (80·8) 7·10 (70·0) 27·3 (44·7)  27·0 (51·6)
tmax (h) 3·0 (1·0–11·0) 5·0 (1·0–8·0) 5·0 (2·0–7·0)  6·0 (2·0–12·0)
AUC0–tlast (nmol h/l) 30·7 (59·9) 43·5 (48·2)  146 (30·6) 154 (32·2)
DHT
Cmax (nmol/l) 1·50 (65·8) 1·89 (53·7) 6·67 (45·7)  6·74 (49·3)
tmax (h) 3·0 (1·0–12·0) 6·0 (1·0–10·0) 7·0 (3·0–9·0)  7·0 (4·0–14·0)
AUC0–tlast (nmol h/l) 7·62 (78·9) 11·0 (73·8) 49·5 (42·0)  57·9 (38·7)
Presented are geometric means (geometric CV%), except for tmax: median (min − max).
n = 24 except for treatment type A, where n = 22 for TU and DHT and n = 23 for DHTU.
Table 2. Effect of food composition on the 
pharmacokinetics of TU, DHTU, testosterone 
and DHT after single oral administration of 
80 mg TU 
Food and bioavailability of oral TU
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decreased 
 
t
 
max
 
 from 5 to 3 h, and increasing the lipid content tended
to delay 
 
t
 
max
 
 from 3 to 6 h.
 
Bioequivalence testing
 
Meals A and B were designed to differ only with regard to the total
amount of lipids (< 1 g 
 
vs.
 
 5 g) and not the amount of calories. There
was a large difference in the total amount of lipids between these two
meals, as well as a signiﬁcant difference between the observed 
 
C
 
max
 
 and
AUC for all analytes. Consequently, ingestion of similar amounts of
calories with different lipid amounts led to a different extent of exposure.
As is already clear from the pharmacokinetic proﬁles, there were
signiﬁcant food effects observed for all analytes on comparing AUC
and 
 
C
 
max
 
 of meal A 
 
vs.
 
 meal C and of meal B 
 
vs.
 
 meal C. Comparing
meals C and D by testing for testosterone and DHT showed that these
were bioequivalent for AUC of testosterone and 
 
C
 
max
 
 of DHT but
indeterminant for 
 
C
 
max
 
 of testosterone and AUC of DHT (Table 3).
 
Discussion
 
In this food interaction study a single oral dose of 80 mg TU was
administered to postmenopausal women after ingestion of various
types of meals. It was demonstrated that the amount of lipids in
a meal considerably inﬂuences the bioavailability of oral TU. A
‘normal’ meal (meal C) increased serum testosterone to a similar
extent as a ‘fatty’ meal (meal D). A meal with a low calorie amount
and low lipid content also led to a low exposure of testosterone
and its precursor (TU) or metabolites (DHTU, DHT).
Postmenopausal women were selected for this study because they
already have low endogenous testosterone levels and do not need a
long-term washout period from previous androgen therapy, as
would be the case in hypogonadal males, or downregulation with a
GnRH agonist, as would be the case in healthy male volunteers
(either of which would have ethical and pathophysiological impli-
cations). The most common daily dose of oral TU prescribed in
hypogonadal men is 80 mg in the morning and 80 mg in the evening.
Therefore, the regimen chosen for this study was 80 mg TU as an
oral single dose, given with four different kinds of food.
In the vast majority of cases testosterone supplementation is
prescribed in men rather than women. Although it is known that
there are sex differences in metabolic clearance rates and distribution
volumes of testosterone,
 
14
 
 this is not considered relevant for an
investigation of the effects of food composition on testosterone
absorption in a crossover study, where each subject acted as her own
control. Moreover, food uptake and lymphatic absorption of
lipophilic food ingredients are both not known to be different
between men and women. It should be realized, however, that
because of the sex differences in testosterone metabolism, the results
obtained in this study in postmenopausal women on absolute
testosterone serum levels cannot automatically be applied to
hypogonadal men.
By comparing a meal with similar amounts of calories (meal A/B)
but different amount of lipids (< 1 g 
 
vs.
 
 5 g) it was shown that bio-
availability increases with increasing amounts of lipids. For example,
the AUC for TU was 41·7  nmol  h/l (meal  A) 
 
vs.
 
  103 nmol h/l
(meal  B) and for testosterone the corresponding ﬁgures were
30·7 nmol h/l 
 
vs.
 
 43·5 nmol h/l, respectively. It is clear that not all
analytes were similarly affected by the amount of lipids in the meal.
However, from these data it is also clear that there seems to be a max-
imum to the amount of lipids needed to get efﬁcient absorption of
TU after oral administration. There were no statistical differences
seen in exposure after a meal with 19 g or 44 g of lipids, indicating
that a lipid amount of 19 g is already sufﬁcient for efﬁcient uptake
and that increasing the amount of lipid over 19 g does not lead to a
higher exposure. This is an important ﬁnding because testosterone
levels need to be restored to physiological levels, and during oral
administration of TU they do not increase indeﬁnitely with increasing
amounts of fat.
Table 3. Bioequivalence testing on the main analytes for the comparison of different meal compositions with meal C (reference)
Analyte Parameter (units) Point estimate 90% CI Conclusion*
Meal A (test) vs. meal C (reference)
Testosterone Cmax (nmol/l) 0·17 0·14–0·21 Not bioequivalent
AUC0–tlast (nmol h/l) 0·21 0·18–0·25 Not bioequivalent
DHT Cmax (nmol/l) 0·22 0·18–0·27 Not bioequivalent
AUC0–tlast (nmol h/l) 0·15 0·12–0·19 Not bioequivalent
Meal B (test) vs. meal C (reference)
Testosterone Cmax (nmol/l) 0·26 0·21–0·33 Not bioequivalent
AUC0–tlast (nmol h/l) 0·30 0·25–0·35 Not bioequivalent
DHT Cmax (nmol/l) 0·29 0·24–0·36 Not bioequivalent
AUC0–tlast (nmol h/l) 0·23 0·18–0·29 Not bioequivalent
Meal D (test) vs. meal C (reference)
Testosterone Cmax (nmol/l) 0·99 0·79–1·25 Indeterminant
AUC0–tlast (nmol h/l) 1·06 0·89–1·25 Bioequivalent
DHT Cmax (nmol/l) 0·99 0·80–1·22 Bioequivalent
AUC0–tlast (nmol h/l) 1·16 0·90–1·49 Indeterminant
Bioequivalent: the 90% conﬁdence interval (CI) is inside the acceptance range of 0·80–1·25. Not bioequivalent: the 90% CI is outside the acceptance range 
and the effect is statistically signiﬁcant (P = 0·05). Indeterminant: the 90% CI is outside the acceptance range and the effect is not statistically signiﬁcant 
(P > 0·05).584 P. G. Schnabel et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Clinical Endocrinology, 66, 579–585
Meals A/B and C/D not only differed in amounts of calories and
lipids but also in consistency because meals A and B were liquid and
meals C and D solid. To what extent this difference contributed to
the difference in exposure needs to be further investigated, but it is
clear that a liquid meal consisting only of yoghurt and milk, with at
most 5 g of lipid, is not sufﬁcient for adequate absorption of oral TU.
The effects of different vehicles on absorption of oral TU have
been tested in the rat. It was proven that oral TU dissolved in long-
chain fatty acid esters was better absorbed by the lymphatic system
than oral TU dissolved in medium- or short-chain fatty acids. However,
the solubility of oral TU in some of these oils was limited.
15 During
the initial development in the 1970s, oleic acid was chosen as the best
compound, combining solubilization and absorption. Recently, the
solvent was changed to castor oil, enabling better storage conditions.
4
When the testosterone ester is orally administered together with a
lipid, part of the compound is incorporated in chylomicrons formed
during lipid digestion in the intestine and coabsorbed with the lipid
into the lymphatic system. During absorption, TU is partly reduced
to DHTU, which is also absorbed by the lymphatic system. From the
lymphatic system, TU and DHTU are then released into the systemic
circulation by the thoracic duct. Subsequent hydrolysis of the ester
liberates testosterone and DHT, which then follow exactly the same
pathway in the body as the endogenous hormones. In a validated
dog model, it has been demonstrated that lymphatic absorption
is responsible for most of the testosterone entering the systemic
circulation after administration of oral TU.
16
In general, lymphatic absorption is known to be enhanced by food,
speciﬁcally by lipids. This has been demonstrated in a validated dog
model with halofantrine,
17 as well as in humans with experimental
10
and registered formulations of oral TU.
11 In the last study, two capsules
of oral TU (80 mg) were administered in postmenopausal women
as a single dose with food (460 kcal and 23 g lipids) vs. administration
of the same without food. Administration of oral TU with food
resulted in a Cmax  of testosterone of 37  nmol/l as compared to
2·4 nmol/l in the fasted group (16-fold difference), whereas the
corresponding values for AUC were 195 vs. 19 nmol h/l (10-fold dif-
ference), respectively. In the current study it was found that a ‘normal
meal’ (with a lipid amount of 19 g) resulted in a marked increase in
testosterone levels and that a ‘fatty meal’ (with a lipid amount of 44 g)
did not result in a further increase in testosterone absorption. These
ﬁndings suggest that, with the ‘normal’ meal, the lymphatic absorp-
tion capacity for testosterone undecanoate has already reached its
maximum and that a further increase in the dietary fat does not fur-
ther enhance lymphatic absorption. The ﬁndings from the current
study, however, also suggest that a low-calorie breakfast, for example
a breakfast consisting of fruit and juice only, is probably not enough
for adequate lymphatic absorption of oral TU.
The American Heart Association (AHA) recommends that up to
30% of the total caloric intake should come from fat.
18 In addition
to being a major energy source, fat is also essential for isolation, vita-
min production and many immunological and metabolic processes.
For an average 2500 kcal diet this means that 750 kcal should come
from fat, which corresponds to a daily total of 83 g of fat (the caloric
value of fat is 9 kcal/g). This AHA recommendation of 83 g is more
than double the 38 g (2 × 19 g) of fat that is needed for adequate
absorption of oral TU per day when taken in a regimen of 2 × 2 capsules
per day. From this calculation it also becomes clear that a ‘normal’
meal contains enough fat for adequate absorption of oral TU.
The current study also revealed that with oral TU there is a con-
siderable interindividual variability in exposure to testosterone: 50%
for Cmax and 40% for AUC. These interindividual differences may,
in individual cases, result in subnormal serum testosterone levels.
This may be related to the variable absorption of TU due to the oral
administration route. Therefore, subjects in whom testosterone is
not adequately supplemented with a standard dose of oral TU are
advised either to increase their daily dosage or to switch to an alternative
testosterone formulation. However, for meals C and D the bioavail-
ability per individual in relation to the other individuals appears
fairly consistent. For example, 20 of the 24 women had a serum
testosterone AUC below or above the median AUC for meal C as well
as meal D. Thus, the lower or higher bioavailability of testosterone
of an individual after oral administration of TU seems to be fairly
reproducible when administered after meals C and D.
From placebo-controlled clinical trials with objective clinical
end-points, it can be concluded that, overall, the total testosterone
exposure in subjects treated with oral TU is probably sufﬁcient
because the magnitude of effects is not different from other testo-
sterone preparations. For example, in a recent study with oral TU
160 mg/day,
19 the increase in muscle mass and reduction in fat mass
were similar to those previously reported for testosterone injection,
20
patch
21,22  or gel
23,24  preparations at standard doses. The clinical
equivalence of oral TU with gel or patch formulations was recently
conﬁrmed by a consensus paper that has been adopted by several
scientiﬁc bodies including the International Society of Andrology.
25
The pharmacokinetic behaviour as observed with oral TU can some-
times make it difﬁcult to monitor treatment adequacy in an indi-
vidual by checking serum testosterone levels. In such cases it is
recommended to monitor the adequacy of the dose by assessment
of the clinical response to treatment, preferably approximately
3 months after start of therapy, when the patient is usually seen back
by the physician.
From this well-controlled pharmacokinetic study it can be con-
cluded that lipid content in food inﬂuences absorption of oral TU.
A liquid meal with, at most, 5 g of lipid is not sufﬁcient for adequate
absorption. It is, however, also not necessary to administer oral TU
with a ‘fatty’ meal; a ‘normal’ meal containing approximately 19 g
of lipid efﬁciently increases serum testosterone levels after oral
administration of TU capsules.
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